Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.43) by 23.26 percent. The company reported quarterly sales of $44.755 million which beat the analyst consensus estimate of $37.617 million by 18.98 percent. This is a 17.44 percent increase over sales of $38.109 million the same period last year.